Statins, Caloric Restriction and Longevinex® in a One-eyed Patient with Macular Drusen
Anish Bhandari *
Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, IL 60064, USA.
Mansi Katkar
Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, IL 60064, USA.
Stuart Richer
Chicago Medical School, Rosalind Franklin University of Medicine and Science, Family & Preventive Medicine, Captain James A Lovell Federal Health Care Center, North Chicago, IL 60064, USA.
William Stiles
Captain James A Lovell Federal Health Care Center, North Chicago, IL 60064, USA.
*Author to whom correspondence should be addressed.
Abstract
Aims: Evaluate the effects of Longevinex®, Statins, and caloric restriction in a one-eyed patient with Dominant Drusen.
Presentation of Case: A 44-year old male patient with OD congenital amblyopia (20/800 VA) and persistent OS confluent drusen (20/20 VA) (Dominant Drusen) was prescribed AREDS I supplementation for 13 years, with stabile vision and retinal exams. Subsequently, the patient developed worrisome OS Amsler grid distortion along with OS sub-retinal drusenoid deposits (SDD) and retinal architecture disruption.
Discussion: A significant increase in the drusen-free macular area (DFMA) of the patient occurred following 2 years of statin drugs and weight reduction and 4 years daily intake of a caloric restriction mimetic nutrient capsule. Only the Longevinex® red wine matrix nutrient complex resulted in complete Amsler grid resolution and sustainable normalisation of his retinal SD-OCT architecture.
Conclusion: This case provides a longitudinal perspective on a novel therapy for SDD amelioration with promising results. Within the context of previously published research on Longevinex®, this approach potentially provides an efficient, cost effective, and compassionate strategy for patients at risk for AMD as well.
Keywords: AMD, drusen, Longevinex®, resveratrol, statin